Ankara Üniversitesi Tıp Fakültesi Mecmuası 0365-8104 1307-5608 Ankara University Clinical Microbiology Klinik Mikrobiyoloji SARS-CoV-2 and Mycobacterium Fortuitum Coinfection: A Case Report SARS-CoV-2 ve Mycobacterium Fortuitum Koenfeksiyonu: Olgu Sunumu https://orcid.org/0000-0003-2989-0548 Gül Gültaze ANKARA ÜNİVERSİTESİ, ANKARA TIP FAKÜLTESİ https://orcid.org/0000-0003-0248-7716 Gülten Ezgi ANKARA UNIVERSITY, ANKARA FACULTY OF MEDICINE https://orcid.org/0000-0003-1106-4977 Maraş Hatice ANKARA UNIVERSITY, ANKARA FACULTY OF MEDICINE https://orcid.org/0000-0002-6093-5137 Demir Özgür ANKARA ÜNİVERSİTESİ, ANKARA TIP FAKÜLTESİ https://orcid.org/0000-0002-7635-8848 Çınar Güle ANKARA UNIVERSITY, ANKARA FACULTY OF MEDICINE https://orcid.org/0000-0001-5136-9148 Akdemir Kalkan İrem Ankara University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology https://orcid.org/0000-0002-7613-2398 Sarıcaoğlu Elif Mukime ANKARA UNIVERSITY, ANKARA FACULTY OF MEDICINE https://orcid.org/0000-0001-9705-1792 Uslu Ebru ANKARA UNIVERSITY, ANKARA FACULTY OF MEDICINE https://orcid.org/0000-0002-5599-6488 Birengel Mehmet Serhat ANKARA UNIVERSITY, ANKARA FACULTY OF MEDICINE 07 01 2025 78 2 157 160 04 19 2025 06 27 2025 Copyright © 1947, Ankara Üniversitesi Tıp Fakültesi Mecmuası 1947 Ankara Üniversitesi Tıp Fakültesi Mecmuası

Coronavirus disease-2019 (COVID-19) pandemic caused millions of people to become infected and had resulted several deaths. After initial resolution, in cases of clinical deterioration, it is essential to consider the possibility of coinfections. Non-tuberculous mycobacteria infections are rare and often overlooked. In this report, we present a severe acute respiratory syndrome-Coronavirus-2 and Mycobacterium fortuitum coinfected patient. Our intention is to bring attention to the possibility of such coinfection without a known history of any lung diseases or immunosuppression other than COVID-19 and thus, broadening the clinical thinking process of physicians

Koronavirüs hastalığı-2019 (COVID-19) pandemisi milyonlarca insanın enfekte olmasına ve çok sayıda ölüme neden olmuştur. Başlangıçtaki iyileşme döneminin ardından klinik kötüleşme olması halinde koenfeksiyon olasılığını düşünmek gerekmektedir. Tüberküloz dışı mikobakteri enfeksiyonları nadir olup sıklıkla gözden kaçırılmaktadır. Bu yazıda şiddetli akut solunum sendromu-Koronavirüs-2 ve Mycobacterium fortuitum koenfeksiyonu olan bir hasta sunmaktayız. Amacımız, eşlik eden akciğer hastalığı ve COVID-19 dışında immünosüpresyon öyküsü bulunmadığında da bu koenfeksiyonun gelişebileceğine dikkat çekmek ve hekimlerin klinik yaklaşımına katkı sağlamaktır

 SARS-CoV-2 non-tuberculous mycobacteria COVID-19 SARS-CoV-2 tüberküloz dışı mikobakteri COVID-19 1. Griffith DE, Aksamit T, Brown-Elliott BA, et al. ATS mycobacterial diseases subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416. 2. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56:2000535. 3. Lange C, Böttger EC, Cambau E, et al. Expert panel group for management recommendations in non-tuberculous mycobacterial pulmonary diseases. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis. 2022;22:e178-e190. 160 4. Wu HY, Chang PH, Chen KY, et al. GREAT working group. Coronavirus disease 2019 (COVID-19) associated bacterial coinfection: incidence, diagnosis and treatment. J Microbiol Immunol Infect. 2022;55:985-992. 5. Rodriguez JA, Bonnano C, Khatiwada P, et al. COVID-19 coinfection with Mycobacterium abscessus in a patient with multiple myyeloma. Case Rep Infect Dis. 2021;2021:8840536. 6. Tsai YC, Huang WC, Mao YC, et al. Mycobacterium fortuitum infection from needlefish impalement during diving: a diagnostic challenge. Travel Med Infect Dis. 2021;41:102056. 7. Singh Bhalla G, Grover N, Singh G, et al. Prevalence of non tuberculous mycobacterial infection in surgical site infections and their antibiotic susceptibility profile. Med J Armed Forces India. 2021;77:343-348. 8. Yeap KC, Sivagurunathan PD, Raman P, et al. Non-tuberculous mycobacterial ocular infection masquerading as choroidal tumour - a diagnostic conundrum. GMS Ophthalmol Cases. 2019;9:Doc25. 9. Cong J, Wang C, Ma L, et al. Septicemia and pneumonia due to Mycobacterium fortuitum infection in a patient with extronodal NK/T-cell lymphoma, nasal type: a case report. Medicine (Baltimore). 2017;96:e6800. 10. d’Incau S, Vargas MI, Calmy A, et al. Mycobaterium fortuitum disseminated infection in an immunocompetent patient without predisposing factors. BMJ Case Rep. 2020;13:e235842. 11. Dahl VN, Mølhave M, Fløe A, et al. Global trends of pulmonary infections with non-tuberculous Mycobacteria: a systematic review. Int J Infect Dis. 2022;125:120-131. 12. Kodana M, Tarumoto N, Kawamura T, et al. Utility of the MALDITOF MS method to identify non-tuberculous mycobacteria. J Infect Chemother. 2016;22:32-35. 13. CLSI. Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. 2nd Edition. CLSI supplement M24S. Clinical and Laboratory Standards Institute; 2023. 14. Siddique N, Roy M, Ahmad S. Mycobacterium fortuitum abscess following breast nipple piercing. IDCases. 202021:e00847.